Eclampsia and Its Treatment Modalities: A Review Article.
eclampsia
end organ dysfunction
hypertension
proteinuria
seizures
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
25
08
2022
accepted:
12
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Hypertension in pregnancy is one of the major contributors to mortality and morbidity. Pregnant women and fetuses are both at high risk of the severe complications of preeclampsia known as eclampsia. Eclampsia is a disorder that requires immediate detection and treatment. Eclampsia and preeclampsia during pregnancy are known to cause morbidity and even death in both the mother and fetus if not properly diagnosed. Chronic hypertension, prenatal hypertension, preeclampsia on top of chronic hypertension, and eclampsia are the four types of hypertension. Preeclampsia is the precursor to eclampsia. Associated with end-organ failure and proteinuria after 20 weeks of pregnancy, preeclampsia is characterized by the development of hypertension with systolic blood pressure (BP) of at least 140 mmHg and/or diastolic BP of at least 90 mmHg. It can lead to the failure of the liver, thrombocytopenia, pulmonary edema, central nervous system (CNS) abnormalities, and renal dysfunction. The emergence of new generalized tonic-clonic seizures in a pregnant woman with preeclampsia is known as eclampsia. Eclamptic seizures can happen prior to delivery, 20 weeks following conception, during delivery, and after delivery. Although rare, gestational trophoblastic illness has been associated with seizures that start before 20 weeks. In this article, we examine the pathogenesis, causes, signs, symptoms, and treatment modalities in patients with eclampsia.
Identifiants
pubmed: 36249647
doi: 10.7759/cureus.29080
pmc: PMC9555679
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e29080Informations de copyright
Copyright © 2022, Akre et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Rev Bras Ginecol Obstet. 2019 May;41(5):318-332
pubmed: 31181585
J Clin Endocrinol Metab. 2013 Aug;98(8):3165-73
pubmed: 23783101
N Engl J Med. 1954 Jan 21;250(3):89-98
pubmed: 13119851
ScientificWorldJournal. 2018 Dec 6;2018:6268276
pubmed: 30622442
JAMA Netw Open. 2022 Aug 1;5(8):e2228093
pubmed: 36001318
J Emerg Med. 1993 Mar-Apr;11(2):169-74
pubmed: 8505522
Stroke. 2009 Apr;40(4):1169-75
pubmed: 19211496
Lancet. 2017 Apr 15;389(10078):1514-1515
pubmed: 28422021
Am J Obstet Gynecol. 1992 Jun;166(6 Pt 1):1757-61; discussion 1761-3
pubmed: 1615984
Hypertens Pregnancy. 2006;25(2):47-62
pubmed: 16867912
Implement Sci Commun. 2020 Oct 02;1:84
pubmed: 33024958
Obstet Gynecol. 2011 Apr;117(4):805-811
pubmed: 21383643
J Perinatol. 1999 Mar;19(2):138-43
pubmed: 10642976
Front Public Health. 2022 Aug 01;10:968045
pubmed: 35979462